From a translational point of view, deletion of PHD2 in aSMCs would be especially informative to better understand the pathophysiology of PAH, however, the current limitation is that there is no selective Cre driver line for conditional gene modifications in aSMCs [15]. The gene discussed is EGLN1; the disease is pulmonary arterial hypertension.